To paraphrase Bill Parcell, "You are what your sto
Post# of 36536
We are competing for investors money and clearly they see more compelling opportunities elsewhere. It seems there are too many questions regarding finance and revenue for investors. The hype builds and the stock price goes up but when the CC or the PR comes the stock price sinks back ... probably for several reasons. Why didn't Merck buy us out? Why is there no definitive agreement with Merck? Why is China not giving us all the money? Is Bintai paying the bills? Will there be a need for a COVID vaccine after this year? Can we compete with the other 20 vaccines?
My opinion is that we will be stuck here until revenue starts being generated ... or at least a guarantee of revenue ...